- Home
- YI vs IMRX Comparison
YI vs IMRX Comparison
Compare YI & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YI
- IMRX
- Stock Information
- Founded
- YI 2010
- IMRX 2008
- Country
- YI China
- IMRX United States
- Employees
- YI N/A
- IMRX N/A
- Industry
- YI Retail-Drug Stores and Proprietary Stores
- IMRX Biotechnology: Pharmaceutical Preparations
- Sector
- YI Consumer Staples
- IMRX Health Care
- Exchange
- YI Nasdaq
- IMRX Nasdaq
- Market Cap
- YI 69.4M
- IMRX 62.7M
- IPO Year
- YI N/A
- IMRX 2021
- Fundamental
- Price
- YI $8.61
- IMRX $1.52
- Analyst Decision
- YI
- IMRX Strong Buy
- Analyst Count
- YI 0
- IMRX 3
- Target Price
- YI N/A
- IMRX $11.00
- AVG Volume (30 Days)
- YI 34.8K
- IMRX 165.5K
- Earning Date
- YI 03-20-2025
- IMRX 03-20-2025
- Dividend Yield
- YI N/A
- IMRX N/A
- EPS Growth
- YI N/A
- IMRX N/A
- EPS
- YI N/A
- IMRX N/A
- Revenue
- YI $1,973,017,082.00
- IMRX N/A
- Revenue This Year
- YI N/A
- IMRX N/A
- Revenue Next Year
- YI N/A
- IMRX N/A
- P/E Ratio
- YI N/A
- IMRX N/A
- Revenue Growth
- YI N/A
- IMRX N/A
- 52 Week Low
- YI $0.41
- IMRX $1.00
- 52 Week High
- YI $11.35
- IMRX $3.83
- Technical
- Relative Strength Index (RSI)
- YI 49.50
- IMRX 38.83
- Support Level
- YI $9.13
- IMRX $1.60
- Resistance Level
- YI $10.52
- IMRX $1.91
- Average True Range (ATR)
- YI 0.85
- IMRX 0.11
- MACD
- YI -0.21
- IMRX 0.01
- Stochastic Oscillator
- YI 36.03
- IMRX 9.30
About YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.